InnoCare’s TYK2 inhibitor soficitinib meets primary endpoint in phase 2 vitiligo trial

InnoCare Pharma announced that its TYK2 inhibitor soficitinib achieved the primary endpoint in a phase 2 study of non‑segmental vitiligo conducted at sites in China. The trial evaluated daily oral dosing for 24 weeks and measured change in the Facial Vitiligo Area Scoring Index (F‑VASI).

At week 24, the high‑dose group showed a 41.2% reduction in F‑VASI, the low‑dose group a 38.8% reduction, while placebo participants improved only 2.2%. Both active doses were statistically superior to placebo, allowing the study to meet its predefined success criteria.

The company reported a favorable safety and tolerability profile consistent with expectations for this class of drugs, though detailed safety data were not disclosed. With the positive readout, InnoCare plans to advance the program into the phase 3 portion of its ongoing phase 2/3 trial.

The result adds to growing interest in TYK2 inhibition for vitiligo, a space already occupied by FDA‑approved Opzelura (a JAK/TYK2 inhibitor) and other candidates from Takeda, Bristol Myers Squibb and others.